Form 4: DEXCOM CEO Leach Reports PSU Vesting, Tax Withholding

Dexcom's President, CEO, and Director, Jacob Steven Leach, reported the vesting of performance-based restricted stock units and subsequent tax withholding, increasing his direct beneficial ownership.

Summary

• Jacob Steven Leach, President, CEO, and Director of Dexcom Inc. (DXCM), reported changes in his beneficial ownership of common stock.
• On January 29, 2026, 8,310 shares were acquired due to the vesting of performance-based restricted stock units (PSUs) granted on March 8, 2023, following the achievement of performance conditions.
• Concurrently, 3,058 shares were disposed of at a price of $73.36 to cover tax withholding and remittance obligations related to the net settlement of these PSUs.
• Following these transactions, Leach directly beneficially owns 337,051 shares of common stock.
• This direct ownership includes 84,537 unvested restricted stock units with various vesting schedules extending through March 8, 2028, and 102 shares from the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.
• Leach also indirectly beneficially owns 47,296 shares through family holdings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation practices and the achievement of previously set performance targets, with no significant positive or negative implications for the company's immediate outlook.

Positives

• Vesting of 8,310 performance-based restricted stock units indicates the achievement of performance conditions set by the company.
• The CEO's continued significant direct and indirect beneficial ownership of 337,051 and 47,296 shares, respectively, aligns his interests with shareholders.

Negatives

• Disposition of 3,058 shares for tax withholding, while a routine event, reduces the number of shares directly held by the CEO.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the vesting of performance-based restricted stock units and subsequent tax withholding are standard practices in executive compensation across the medical device and technology sectors. This routine transaction reflects the achievement of pre-defined corporate performance metrics, common for incentivizing leadership in growth-oriented companies like Dexcom.

Related Party Transactions

• Indirect beneficial ownership of 47,296 shares is held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with the Reporting Person's spouse serving as a trustee. This constitutes a related party holding.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates that the company met certain performance goals, which could be viewed positively. The CEO's continued significant ownership aligns his interests with shareholders.
• Employees: The mention of shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan suggests broad-based employee equity participation.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of performance-based restricted stock units and subsequent tax withholding. These transactions are expected and do not provide new information that would significantly alter the investment thesis for Dexcom. The CEO's continued substantial ownership is a positive for alignment, but the overall impact on the stock's valuation is neutral. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for a change in investment strategy.

Keywords

Dexcom, DXCM, Jacob Steven Leach, Form 4, SEC filing, beneficial ownership, restricted stock units, PSUs, insider transaction, executive compensation, stock vesting, tax withholding